- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 3, 2022
Product Development
GSK sees commercial opportunity in antimicrobial resistance
Pharma stops trials of antibiotic gepotidacin early for efficacy as it deepens commitment to fighting AMR
BioCentury | Oct 4, 2022
Distillery Therapeutics
An antimicrobial DNA gyrase inhibitor for tuberculosis
BioCentury | Sep 22, 2022
Deals
GSK deal revives Spero’s clinical plan for oral antibiotic
Pharma pays $66M up front, allowing Spero to start a second Phase III trial following a complete response letter
BioCentury | Jun 4, 2022
Discovery & Translation
Killing malaria at any life cycle stage; plus GSK’s primate plague data and more
BioCentury’s roundup of translational news
BioCentury | Apr 29, 2020
Emerging Company Profile
Bugworks: breaking the U.S.-centric antimicrobial mold
Bugworks’ broad-spectrum antibiotics inhibit DNA replication while avoiding common resistance mechanism
BioCentury | Jul 25, 2019
Distillery Therapeutics
Phenylisoxazole-quinoline-based DNA gyrase inhibitor for drug-resistant
BioCentury | Jun 20, 2019
Company News
Spero's TB program first licensing deal for Gates Medical Research Institute
Items per page:
1 - 10 of 197